Introduction We develop a multiplex quantitative realtime PCR for synchronized analysis of mitochondrial DNA (mtDNA) and nuclear DNA (nDNA) to investigate relative mtDNA abundance in paired normal and cancerous breast tissues.
Introduction
Human cells have a nuclear genome and additional cytoplasmic genomes that are compartmentalised in the mitochondria. In comparison to nuclear genomic DNA, mitochondrial DNA (mtDNA) reveals high mutation rates caused by constant exposure to mutagenic oxygen radicals and lacks the protective mechanisms of DNA repair. These properties of mtDNA suggest their potential importance in ageing, apoptosis and especially carcinogenesis (Zhang and Qi 2008; .
Qualitative aberrations of mtDNA, such as mutations, have been found in solid tumours, such as colon, stomach, liver, kidney, bladder, prostate, skin and lung cancer (Copeland et al. 2002; Penta et al. 2001) , and in haematological malignancies, such as leukaemia and lymphoma (Fontenay et al. 2006) . Quantitative aberrations of mtDNA have been observed in various sample types from patients with cancers (Mambo et al. 2005) . While increased mtDNA content has been found in prostate (Mizumachi et al. 2008a) , head and neck (Kim et al. 2004 ), endometrial adenocarcinoma (Wang et al. 2005) , etc., reduced mtDNA content in renal (Meierhofer et al. 2004 ) and liver cancers (Yin et al. 2004 ) has been reported.
Because of these mutations and the quantitative aberrations involved in the development of human cancers, mtDNA may have promising clinical applications for cancers (Jiang et al. 2005; Jain 2007) . Decreased mitochondrial DNA copy number is correlated with tumour progression and prognosis in Chinese breast cancer patients (Yu et al. 2007) . Increased mtDNA content in saliva is associated with head and neck cancer (Mizumachi et al. 2008b) . High levels of cell free circulating mtDNA in prostate cancer patients with poor prognosis could be a valuable predictor of prognosis (Ellinger et al. 2008; Mehra et al. 2007 ). Furthermore, mtDNA aberrations play important roles in response to cancer therapy, for example, causing resistance to therapeutic agents (Mizumachi et al. 2008b; Chen et al. 2007) .
In the present study, we developed a simple and accurate multiplex real-time PCR method for synchronised quantiWcation of nuclear DNA (nDNA) and mtDNA in paired adjacent normal and cancerous breast tissue samples from 51 patients with breast cancer. The content of MTATP8 gene on mtDNA in the cancerous tissues was compared with that in normal tissues from the same patients. We analysed the correlation between the content of mtDNA in tissues and the traditional pathological parameters and clinical predictive markers.
Materials and methods

Samples
The study was approved by the local institutional review board. ParaYn-embedded sections from adjacent normal and cancerous breast tissue samples were examined by two experienced pathologists. Breast cancer characteristics, the histological grading; hormone receptor status and biomarkers from the breast cancer patients are listed in Table 1 . DNA was extracted from three to Wve sections of each 10 m thick paraYn-embedded sample (around 0.01-0.02 g of tissue) using a High Pure PCR Template Preparation Kit (Roche Diagnostics, Germany) and eluted into 150 l of elution buVer. The eluted DNA was stored at ¡20°C until further use.
Real-time PCR
The amounts of nDNA and mtDNA were quantiWed by multiplex TaqMan real-time PCR for both GAPDH gene of nDNA and MTATP 8 gene of mtDNA starting at locus 8446. The GAPDH and MTATP 8 primer and probe sequences are shown as follows: GAPDH (forward):5Ј CCC CAC ACA CAT GCA CTT ACC3Ј; (reverse): 5ЈCCT AGT CCC AGG GCT TTG ATT 3Ј; probe 5Ј (MGB) TAG GAA GGA CAG GCA AC (VIC) 3Ј. MTATP 8 (forward): 5Ј AAT ATT AAA CAC AAA CTA CCA CCT ACC 3Ј; (reverse): 5Ј TGG TTC TCA GGG TTT GTT ATA 3Ј; probe: 5Ј (MGB) CCT CAC CAA AGC CCA TA (FAM) 3Ј.
The PCR was performed using the ABI PRISM 7000 Sequence Detection System (Applied Biosystems, ABI). A total of 2.5 l of DNA were used as template for the PCR analysis. The real-time PCR were carried out in 25 l of total reaction volume using a 2 min incubation at 50°C, followed by an initial denaturation step at 95°C for 10 min and 40 cycles of 1 min at 60°C and 15 s at 95°C.
To determine the quantities of mtDNA and nDNA present in tissue samples, standard dilution curves using HPLCpuriWed single-stranded synthetic DNA oligonucleotides (Microsynth) specifying a 79-bp MTATP 8 gene amplicon and a 97-bp GAPDH amplicon with concentration ranging from 5 £ 10 7 copies to 5 £ 10 2 copies, were used. We examined the ampliWcation eYciency for both GAPDH and MTATP 8 on experimental serial dilutions. The ampliWcations of mtDNA and nDNA on serial dilutions showed a good correlation with comparable eYciencies. A threshold cycle (Ct) reXects the cycle number at which a Xuorescence signal within a reaction crosses a threshold. In our study, the average threshold cycle number (Ct) values of the nDNA and mtDNA were obtained from each case. The content of mtDNA was calculated using the delta Ct ( Ct) of average Ct of mtDNA and nDNA ( Ct = CtnDNA ¡ CtmtDNA) in the same well as an exponent of 2 (2 Ct ).
Statistical analysis
The data were analysed using SPSS software (Statistical Software Package for Windows v. 15.0). Content of mtDNA is given as the median, the range and the fold diVerence. Wilcoxon signed ranks test was used to compare the diVerences between ranks of each paired samples. The Mann-Whitney U test and Kruskal-Wallis test was used to compare the content of mtDNA in normal adjacent normal tissues and cancerous tissues. The Spearman rank test was applied to analyse the relationship of mtDNA content between normal tissues and cancerous tissues.
Results
Co-extraction of mtDNA and nDNA from the paired breast tissue samples Nuclear DNA and mtDNA were co-extracted from the paraYn-embedded sections. The average Ct values for GAPDH sequence, representing total nDNA, ranged from 24.42 to 37.08 in cancerous tissues and from 25.19 to 38.38 in normal tissues, respectively. The average Ct values for MTATP 8 gene sequence, representing total mtDNA, ranged from 18.48 to 32.54 in cancerous tissues and from 19.28 to 33.42 in normal tissues, respectively. The average Ct values of mtDNA were less than those of nDNA in all cases, represented higher amounts of mtDNA than those of nDNA in the breast tissues. While the average Ct values of GAPDH ampliWcation in the normal tissues are correlated with those of MTATP8 gene ampliWcation (Spearman rank test P < 0.001, r = 0.63) (Fig. 1a) , no similar phenomenon was observed in cancerous tissues (P > 0.05, r = 0. 261) (Fig. 1b) , suggesting an alteration of the relationship between nDNA and mtDNA in cancerous tissues.
Content of mtDNA in paired normal and cancerous breast tissues
The Ct values between GAPDH ampliWcation and MTATP 8 gene ampliWcation show a 6.73 cycle diVerence in normal tissues and 2.54 cycle diVerence in cancerous tissues. The Ct values between normal and cancerous tissues shows a 4.2 cycle diVerence ( Ct) (Mann-Whitney U test P < 0.001) ( Table 2) . We calculated the content of mtDNA in the tissues using a formula of 2 Ct . The content of mtDNA in cancerous tissues is signiWcantly lower than that in normal tissues (Mann-Whitney U test P < 0.001) (Fig. 2) . Out of 51 paired samples, 42 pairs show mtDNA in normal tissues > mtDNA in cancerous tissues (Wilcoxon signed ranks test P < 0.001).
Relationship between decreased content of mtDNA and other established prognostic factors
In this study, associations between the content of mtDNA in breast tissues and traditional clinical parameters, such as age, tumour type, tumour size, lymph node involvement, extent of metastasis, stage, histological grading, receptor status and pathological biomarkers (HER-2/neu and PS2), were analysed (Table 1) . Decreased content of mtDNA in breast cancer was not associated with age (¸50 vs. <50), tumour type (ductal vs. lobular), tumour size (T1, T2, T3), lymph node involvement (N0 and N1), extent of metastasis (M0 vs. M1), stage, histological grading (I, II, III), HER-2/neu ampliWcations and PS2 detections (Table 1) . However, while we found signiWcantly decreased mtDNA content in normal tissues of an oestrogen receptor (ER) negative detection compared with that of an ER positive detection (mtDNA in normal tissues 89.81 vs. 756.46, P = 0.041; mtDNA in cancerous tissues 6.57 vs. 12.46, P = 0.613) (Fig. 3a) , a signiWcantly decreased content of mtDNA in both normal and cancerous tissues of a progesterone receptor (PR) negative detection compared with that of PR positive tissues was observed (mtDNA in normal tissues 37.67 vs. 434.06, P = 0.016; mtDNA in cancerous tissues 3.77 vs. 20.83, P = 0.037) (Fig. 3b) .
Discussion
In this study, we found that mtDNA content of MTATP 8 gene for encoding ATP synthase was decreased in 42 of 51 (82%) cancerous breast tissues compared to their normal breast tissues collected from same individuals ( Table 2) . This suggests that, as it has been reported for other cancer types, quantitative alterations of mtDNA may be a potential biomarker for breast cancer. Both decrease and increase of mtDNA content in cancers have been shown in many studies, varying with tissue type or origin of tumours, because of diVerent patterns of mitochondrial transcripts coding for proteins involved in oxidative phosphorylation (Lebrecht et al. 2005; Masuyama et al. 2005) .
Decrease of mtDNA has been observed in renal cancer (Meierhofer et al. 2004 ) and hepatocellular carcinoma (Yin et al. 2004 ). However, the pathogenesis of mtDNA decrease in cancers remains unclear. It was hypothesised that mitochondrial respiratory dysfunction and damage of mtDNA, such as mutation, deletion or depletion, in carcinogenesis may course the quantitative alterations (Ye et al. 2008) . Those alterations of mtDNA could correlate with increased risk (Mosquera-Miguel et al. 2008; Bai et al. 2007 ) and increased invasiveness of cancer (Simonnet et al. 2002) . Decreased mtDNA content can cause decreased oxidative phosphorylation capacity that could increase cancer cell growth under hypoxic conditions during cancer development and cancer progression (Rossignol et al. 2004 ). Depletion of mtDNA can also lead to cells resistant to a certain apoptosis pathway during cancer development (Higuchi 2007) .
In our study, mtDNA content was signiWcantly decreased in cancerous breast tissues. However, high copy numbers of mtDNA per cell compared to those of nDNA (from 2 2.535 to 2 6.73 is from 5.8-to 106.2-fold higher in our study) may still increase the sensitivity of testing mtDNA alterations, thus having more promising clinical applications in cancers.
Using QuantiTest SYBR Green PCR, Yu et al. (2007) found that, on a 59 case study, mtDNA copy number alteration is correlated with tumour progression and prognosis in Chinese breast cancer patients. They showed that the reduced copy number in mtDNA was associated with an older onset age (¸50 years old) and a higher histological grade. We compared the decrease in mtDNA content with other traditional clinical parameters, such as age, tumour size, lymph node involvement, extent of metastasis, and predictive markers, such as histological grades, HER-2/neu ampliWcation and PS2 detection. No relationship was found between the decrease and those parameters. It was likewise shown by Mambo et al. (2005) that changes in mtDNA content in breast cancer did not correlate with tumour grade and metastasis, suggesting that these alterations may occur in the early stages of tumorigenesis.
However, in our study, we did Wnd associations between mtDNA content and hormone receptor status. MtDNA content is signiWcantly higher in ER positive normal breast tissues than that in ER negatives, suggesting that ER status in normal breast tissue may play a part in mtDNA function. Chen et al. (2004) observed that ER is present in mitochondria of human MCF7 cells, implying that oestrogens can have an eVect on mitochondrial via ER in regulation of mitochondrial respiratory chain structure and function (Chen et al. 2005; Yager and Chen 2007) . A similar phenomenon was not shown in the cancerous tissues. We presume that mtDNA dependent ER action may be altered during cancer development in vivo.
In our study, we also observed that changes in mtDNA content are associated with PR in both normal and cancerous tissues (mtDNA in PR positive > that in PR negative). We assume that the changes may be tissue speciWc rather than tumour speciWc. Several studies showed that mitochondria respiration varies during the menstrual cycle and is associated with pregnancy (BuVenstein et al. 1995; Webb 1986) . Mitochondria respiration increases during the progesterone-dominant lucteal phase.
In conclusion, our data suggest that using a robust Taqman real-time PCR, the content of mtDNA in breast tissues can be easily quantiWed. MtDNA content in breast cancer tissues decreased dramatically, and the changes are not associated with most traditional prognostic parameters. Many studies in vitro, using animal models and cell culture models, showed that reduced mtDNA content could lead to cells resistant to apoptosis, favour cancer cell growth, increase invasiveness and contribute to progression and metastasis of cancer cells. Therefore, decrease of mtDNA content in breast cancer may have diagnostic and prognostic value. In this study, we also found hormone receptor related changes in mtDNA content, which may assist us in understanding the biology of mtDNA in gender and age manner.
